Organization
Artiva Biotherapeutics
3 clinical trials
1 abstract
Clinical trial
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus NephritisStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Abstract
AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.Org: Fox Chase Cancer Center, O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Norton Cancer Institute, Texas Oncology PA, OHSU - Oregon Health and Science University,